3 hours Travere Therapeutics’ (TVTX) “Outperform” Rating Reaffirmed at Leerink Partners MarketBeat
Leerink Partners reaffirmed an “outperform” rating and set a $20.00 price target on shares of Travere Therapeutics in a research note on Tuesday.
Leerink Partners reaffirmed an “outperform” rating and set a $20.00 price target on shares of Travere Therapeutics in a research note on Tuesday.